Rare disease specialist SynaptixBio Ltd has got its second FDA orphan drug designation for a subtype of TUBB4A leukodystrophy.
Pierre Fabre Médicament SAS has entered into an Asset Purchase Agreement (APA) over pan-RAF programs developed by Kinnate Biopharma Inc.
a:8:{s:8:”location”;a:1:{i:0;a:1:{i:0;a:3:{s:5:”param”;s:9:”post_type”;s:8:”operator”;s:2:”==”;s:5:”value”;s:9:”portfolio”;}}}s:8:”position”;s:15:”acf_after_title”;s:5:”style”;s:7:”default”;s:15:”label_placement”;s:3:”top”;s:21:”instruction_placement”;s:5:”label”;s:14:”hide_on_screen”;s:0:””;s:11:”description”;s:0:””;s:12:”show_in_rest”;i:0;}
a:8:{s:8:”location”;a:1:{i:0;a:1:{i:0;a:3:{s:5:”param”;s:9:”post_type”;s:8:”operator”;s:2:”==”;s:5:”value”;s:4:”post”;}}}s:8:”position”;s:15:”acf_after_title”;s:5:”style”;s:7:”default”;s:15:”label_placement”;s:3:”top”;s:21:”instruction_placement”;s:5:”label”;s:14:”hide_on_screen”;s:0:””;s:11:”description”;s:0:””;s:12:”show_in_rest”;i:0;}
PulseSight Therapeutics SAS was launched on Wednesday, backed by seed financing from Pureos Bioventures and ND Capital. The company introduces a disruptive delivery platform in ophthalmology biotech, focusing on the development of non-viral gene therapies coupled with minimally-invasive delivery technology.
Swiss multivalent vaccine developer LimmaTech Biologics AG has been awarded US$2.2m rom the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
Intracellular cancer target screening specialist Curve Therapeutics Ltd has closed a £40.5m financing led by Pfizer Ventures to advance its preclinical pipeline of small cyclic petides.
German foodtech start-up Pacifico Biolabs has raised US$3.3m to push the development of healthy animal-free, carbon-neutrally produced fish and seafood.
MIP Discovery Ltd has closed a £7M Series A financing to drive commercialisation of its synthetic affinity reagents in cell and gene therapy.
London-based Vidac Pharma Holding plc reported that its Warburg effect blocker VDA-1275 increased efficacy of chemotherapeutics 1000-fold in human organoid cancer models for liver cancer.